HK1205131A1 - 端抑制劑 - Google Patents

端抑制劑

Info

Publication number
HK1205131A1
HK1205131A1 HK15105894.9A HK15105894A HK1205131A1 HK 1205131 A1 HK1205131 A1 HK 1205131A1 HK 15105894 A HK15105894 A HK 15105894A HK 1205131 A1 HK1205131 A1 HK 1205131A1
Authority
HK
Hong Kong
Prior art keywords
hsp90
terminal
inhibitors
hsp90 inhibitors
terminal hsp90
Prior art date
Application number
HK15105894.9A
Other languages
English (en)
Inventor
．布萊格
．庫蘇馬
．森德斯特倫
Original Assignee
Univ Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Kansas filed Critical Univ Kansas
Publication of HK1205131A1 publication Critical patent/HK1205131A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
    • C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
    • C07D319/08—1,3-Dioxanes; Hydrogenated 1,3-dioxanes condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HK15105894.9A 2012-02-09 2015-06-19 端抑制劑 HK1205131A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261597004P 2012-02-09 2012-02-09
PCT/US2013/025387 WO2013119985A1 (en) 2012-02-09 2013-02-08 C-terminal hsp90 inhibitors

Publications (1)

Publication Number Publication Date
HK1205131A1 true HK1205131A1 (zh) 2015-12-11

Family

ID=47754998

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15105894.9A HK1205131A1 (zh) 2012-02-09 2015-06-19 端抑制劑
HK18107629.4A HK1249519A1 (zh) 2012-02-09 2018-06-12 Hsp90c端抑制劑及其醫藥組合物和用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK18107629.4A HK1249519A1 (zh) 2012-02-09 2018-06-12 Hsp90c端抑制劑及其醫藥組合物和用途

Country Status (24)

Country Link
US (6) US9422320B2 (zh)
EP (2) EP3656758B1 (zh)
JP (1) JP6121450B2 (zh)
KR (1) KR102124109B1 (zh)
CN (2) CN107474085B (zh)
AU (1) AU2013216858C1 (zh)
BR (1) BR112014019704B1 (zh)
CA (1) CA2866814C (zh)
CY (1) CY1122358T1 (zh)
DK (2) DK3656758T3 (zh)
EA (1) EA027147B1 (zh)
ES (1) ES2755093T3 (zh)
FI (1) FI3656758T3 (zh)
HK (2) HK1205131A1 (zh)
HR (1) HRP20191940T1 (zh)
HU (1) HUE046939T2 (zh)
LT (2) LT3656758T (zh)
MX (1) MX361233B (zh)
NZ (1) NZ629778A (zh)
PL (1) PL2812341T3 (zh)
PT (2) PT3656758T (zh)
RS (2) RS59719B1 (zh)
SI (1) SI2812341T1 (zh)
WO (1) WO2013119985A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3656758T (pt) 2012-02-09 2024-03-27 Univ Kansas Intermediários para a preparação de inibidores do cterminal de hsp90
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
SG11201610677XA (en) * 2014-06-24 2017-01-27 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers
WO2016145219A1 (en) * 2015-03-10 2016-09-15 University Of Florida Research Foundation, Inc. Treatment of peripheral neuropathies
CN112020506A (zh) 2018-02-07 2020-12-01 里亚塔医药公司 新生霉素类似物与脯氨酸的共晶体形式
IL278698B2 (en) * 2018-05-14 2024-06-01 Reata Pharmaceuticals Inc Bi-aryl amides with sugar groups that are adapted to the treatment of diseases related to the heat stroke protein pathway

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005301957B2 (en) 2004-11-03 2012-02-23 Department Of Health And Human Services Novobiocin analogues as anticancer agents
US9120774B2 (en) 2004-11-03 2015-09-01 University Of Kansas Novobiocin analogues having modified sugar moieties
US8212012B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues having modified sugar moieties
US7622451B2 (en) 2004-11-03 2009-11-24 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
US8212011B2 (en) 2004-11-03 2012-07-03 University Of Kansas Novobiocin analogues
US8846742B2 (en) * 2006-02-14 2014-09-30 The Trustees Of Columbia University In The City Of New York Neuronal pain pathway modulators
GB0620259D0 (en) * 2006-10-12 2006-11-22 Astex Therapeutics Ltd Pharmaceutical compounds
CA2669687C (en) 2006-11-15 2013-09-10 Forest Laboratories Holdings Limited Phthalazine derivatives
MX2009009936A (es) 2007-03-20 2010-02-11 Curis Inc Amino piridina fusionada como inhibidores de hsp90.
US7960353B2 (en) * 2007-05-10 2011-06-14 University Of Kansas Novobiocin analogues as neuroprotective agents and in the treatment of autoimmune disorders
JP5766617B2 (ja) * 2009-02-20 2015-08-19 ユニバーシティ・オブ・カンザス 修飾された糖部分を有するノボビオシン類似体
US20110082098A1 (en) 2009-09-30 2011-04-07 University Of Kansas Novobiocin analogues and treatment of polycystic kidney disease
TW201216957A (en) 2010-07-13 2012-05-01 Dainippon Sumitomo Pharma Co Biarylamide derivative or a pharmaceutically acceptable salt thereof
CN101967125B (zh) * 2010-10-08 2012-07-04 广州暨南生物医药研究开发基地有限公司 一种Hsp90抑制剂Xbj-B16-1及其制备方法与应用
US9546170B2 (en) 2011-04-05 2017-01-17 Sloan-Kettering Institute For Cancer Research Hsp90 inhibitors
US9056104B2 (en) 2011-05-20 2015-06-16 The University Of Kansas Dynamic inhibitors of heat shock protein 90
PT3656758T (pt) 2012-02-09 2024-03-27 Univ Kansas Intermediários para a preparação de inibidores do cterminal de hsp90
EP3066072B1 (en) 2013-11-07 2021-11-03 The University of Kansas Biphenylamide derivative hsp90 inhibitors
EP3068778A2 (en) 2013-11-11 2016-09-21 The University of Kansas Coumarin based hsp90 inhibitors with urea and ether substituents
EP3154964B1 (en) 2014-06-13 2023-04-05 The University of Kansas Triazole modified coumarin and biphenyl amide-based hsp90 inhibitors
SG11201610677XA (en) 2014-06-24 2017-01-27 Univ Kansas Biphenyl amides with modified ether groups as hsp90 inhibitors and hsp70 inducers

Also Published As

Publication number Publication date
CA2866814C (en) 2021-02-16
US10882881B2 (en) 2021-01-05
RS59719B1 (sr) 2020-01-31
CA2866814A1 (en) 2013-08-15
BR112014019704B1 (pt) 2022-05-31
CY1122358T1 (el) 2021-01-27
EP3656758A1 (en) 2020-05-27
PL2812341T3 (pl) 2020-03-31
JP2015506982A (ja) 2015-03-05
US20190023730A1 (en) 2019-01-24
EA027147B1 (ru) 2017-06-30
HRP20191940T1 (hr) 2020-01-10
CN107474085A (zh) 2017-12-15
CN104271587B (zh) 2017-09-12
US9422320B2 (en) 2016-08-23
US10030041B2 (en) 2018-07-24
EA201491496A1 (ru) 2015-01-30
NZ629778A (en) 2016-03-31
SI2812341T1 (sl) 2020-02-28
US20200283465A1 (en) 2020-09-10
DK2812341T3 (da) 2019-11-18
JP6121450B2 (ja) 2017-04-26
KR102124109B1 (ko) 2020-06-17
BR112014019704A8 (pt) 2017-07-11
US11390640B2 (en) 2022-07-19
US20170051000A1 (en) 2017-02-23
EP2812341A1 (en) 2014-12-17
MX2014009608A (es) 2015-05-20
AU2013216858B2 (en) 2017-08-24
CN107474085B (zh) 2021-05-11
LT2812341T (lt) 2019-12-10
PT2812341T (pt) 2019-11-22
US20230102047A1 (en) 2023-03-30
AU2013216858A1 (en) 2014-09-18
HUE046939T2 (hu) 2020-04-28
BR112014019704A2 (zh) 2017-06-20
US20210188891A1 (en) 2021-06-24
US20150057240A1 (en) 2015-02-26
HK1249519A1 (zh) 2018-11-02
US10590157B2 (en) 2020-03-17
DK3656758T3 (da) 2024-04-22
FI3656758T3 (fi) 2024-04-22
PT3656758T (pt) 2024-03-27
MX361233B (es) 2018-11-30
AU2013216858C1 (en) 2018-03-01
CN104271587A (zh) 2015-01-07
RS65412B1 (sr) 2024-05-31
KR20150001729A (ko) 2015-01-06
WO2013119985A1 (en) 2013-08-15
ES2755093T3 (es) 2020-04-21
EP2812341B1 (en) 2019-08-28
LT3656758T (lt) 2024-05-10
EP3656758B1 (en) 2024-03-06

Similar Documents

Publication Publication Date Title
EP2819600A4 (en) CRYOSURGERY SYSTEM
EP2857033A4 (en) SKIN-PUNKING PEPTIDE
HK1207366A1 (zh) 作為 抑制劑的塞二唑啉酮二酮
EP2812347A4 (en) AUTOPHAGIA-INDUCING PEPTIDE
HK1209422A1 (zh) 抑制劑
HK1205131A1 (zh) 端抑制劑
EP2885291A4 (en) INHIBITORS OF VEGFR3
HK1209104A1 (zh) 抑制劑
GB201009853D0 (en) HSP90 inhibitors
HK1209138A1 (en) Peptides
ZA201503275B (en) Transporter
GB201200555D0 (en) Peptide
GB201204868D0 (en) Peptides
EP2891663A4 (en) PEPTIDE DERIVED FROM PSF1
GB201221414D0 (en) Trans-locating peptide
GB201200624D0 (en) Peptide
GB201200623D0 (en) Peptide
AU2012905607A0 (en) Protein Inhibition
GB201220328D0 (en) Peptides
GB201211740D0 (en) Peptides
GB201207895D0 (en) Peptides
GB201200509D0 (en) Peptides
GB201007519D0 (en) Means for inhibiting the expression of rragb